EPRX EUPRAXIA PHARMACEUTICALS INC.

Nasdaq www.eupraxiapharma.com/home/default.aspx


$ 5.48 $ -0.17 (-3.03 %)    

Wednesday, 29-Oct-2025 15:59:54 EDT
QQQ $ 634.57 $ 2.85 (0.45 %)
DIA $ 475.30 $ -0.78 (-0.16 %)
SPY $ 686.59 $ 0.33 (0.05 %)
TLT $ 90.86 $ -0.93 (-1.01 %)
GLD $ 361.85 $ -1.38 (-0.38 %)
$ 5.44
$ 5.60
$ 5.41 x 100
$ 5.90 x 7
$ 5.40 - $ 5.58
$ 2.47 - $ 7.19
45,926
na
184.58M
$ -0.56
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 eupraxia-reports-encouraging-safety-and-efficacy-data-from-eosinophilic-esophagitis-study

Eupraxia's Cohort 9 RESOLVE trial data showed durable remission, improved tissue health, and strong safety, supporting Phas...

Core News & Articles

Gainers SciSparc (NASDAQ: SPRC) shares increased by 28.2% to $5.68 during Monday's after-market session. The company's...

Core News & Articles

Clinical data was reported for the first time in patients receiving an 8 mg dose per injection (Cohort 9 of the dose escalation...

Core News & Articles

Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechn...

Core News & Articles

HC Wainwright & Co. analyst Brandon Folkes reiterates Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Buy and maintains $1...

Core News & Articles

Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported quarterly losses of $(0.26) per share which missed the analyst consensus estima...

Core News & Articles

Cantor Fitzgerald analyst Kristen Kluska initiates coverage on Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Overweight rati...

Core News & Articles

HC Wainwright & Co. analyst Brandon Folkes initiates coverage on Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Buy ratin...

Core News & Articles

Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate...

Core News & Articles

At 9 months active drug continued to be released into the esophagus in patients at a rate similar to what was seen at the 3- an...

Core News & Articles

The Company anticipates that existing cash reserves, and anticipated proceeds from in-the-money warrants, will be sufficient to...

Core News & Articles

Histological scores and symptom scores continue to improve as EP-104GI dose, and area of esophageal coverage, increaseCohort 6 ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION